基于光声成像无创监测索拉非尼治疗肝细胞癌的疗效反应
在肝原位人肝细胞癌(HepG2-RFP)裸鼠模型中,索拉非尼治疗组(n=21)与对照组(n=20)相比,治疗一周后肿瘤及残余健康肝组织的sO2均下降,HIF-1α蛋白表达升高并与凋亡指数相关;肿瘤ΔsO2与坏死分数、凋亡指数呈显著正相关,与微血管密度呈负相关,提示光声成像测量的sO2可作为无创监测疗效的标志物。
要点
- 光声成像可无创测量肝细胞癌及肝实质的sO2,用于监测索拉非尼治疗后的氧合变化。
- 治疗后肿瘤ΔsO2与坏死分数、凋亡指数正相关,与微血管密度负相关。
- 治疗一周后肿瘤及残余健康肝组织sO2下降,肿瘤HIF-1α表达升高并与凋亡指数相关。
核心结论
- 索拉非尼治疗引起肝细胞癌及肝实质sO2变化,并通过缺氧环境诱导HIF-1α积聚;光声成像测量的sO2可作为无创监测原位肝细胞癌小鼠模型治疗反应的标志物。
研究设计与样本
- 动物实验研究,将肝内植入人肝细胞癌(HepG2-RFP)细胞的裸鼠随机分为索拉非尼治疗组(n=21)和对照组(n=20),在基线和一周后以光声成像测量肿瘤体积和sO2,并以荧光成像分析辐射效率及组织学分析评估治疗反应。
关键影像表现/征象
- 治疗一周后,肝细胞癌和残余健康肝组织的sO2均下降。
- 治疗一周后,肝细胞癌的缺氧诱导因子-1α(HIF-1α)蛋白表达升高,且与凋亡指数相关。
- 肝细胞癌的ΔsO2与肿瘤坏死分数和凋亡指数呈显著正相关,与肿瘤微血管密度呈负相关。
诊断标准与关键数值
- 索拉非尼疗效通过坏死分数、凋亡指数和微血管密度(MVD)评估为有效。
- 肝细胞癌ΔsO2与坏死分数、凋亡指数呈显著正相关,与MVD呈负相关。
临床应用与阅片要点
- 光声成像测量的sO2可用于无创监测肝细胞癌索拉非尼治疗后的氧合变化,辅助评估治疗反应。
- 阅片时可关注肿瘤及残余健康肝组织sO2的变化,并结合ΔsO2与坏死分数、凋亡指数及MVD的相关性理解疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: We investigated the changes of tissue oxygen saturation (sO2) in sorafenib-treated HCC (hepatocelluar carcinoma) mouse models using photoacoustic imaging (PI).
MATERIALS AND METHODS: Nude mice, implanted with human HCC (HepG2-RFP) cells in the liver, were randomised to the sorafenib-treated group (n = 21) or the control group (n = 20). Tumour volume and sO2 were measured by PI at baseline and then one week later, and radiant efficiency (RE) and therapeutic response were analysed by fluorescence imaging and histologic analysis.
RESULTS: Sorafenib was effective in treating HCC by evaluating necrotic fraction, apoptosis index, and microvessel density (MVD). One week after treatment, the sO2 of HCC and residual healthy liver tissue decreased, and the hypoxia inducible factor-1α (HIF-1α) protein expression of HCC increased, correlating with the apoptosis index. The ΔsO2 in HCC showed a significantly positive correlation with the necrotic fraction and the apoptosis index of tumour and a negative correlation with the MVD of tumour.
CONCLUSION: Sorafenib treatment results in changes of sO2 in HCC and liver parenchyma and induces the accumulation of HIF-1α by hypoxic environment. sO2 as measured by PI, can be a useful marker for non-invasive monitoring of the therapeutic response in orthotopic HCC mouse models.
KEY POINTS: • Hypoxia is a characteristic feature of the tumour microenvironment • It is important to monitor sO 2 in HCC during sorafenib treatment • PI is useful for non-invasive monitoring of sO 2 in HCC. • ΔsO 2 in HCC showed a significantly correlation with tumour response.
引用
- Lee S, Kim JH, Lee JH, et al. Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging. Eur Radiol. 2017. PMID: 28752217. doi:10.1007/s00330-017-4960-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。